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Abstract
BACKGROUND
Overexpression of heat shock proteins (HSPs) is associated with several
malignancies and contributes to the development, progression, and metastasis of
cancer, in addition to the inhibition of cellular death. In recent years, there has
been active research into using HSP inhibitors in several malignancies. Due to the
poor prognosis of esophageal adenocarcinoma (EAC), it would be valuable to
find new biomarkers for the development of cancer treatments.
AIM
To evaluate the expressions of HSP27 and HSP70 and their effect on survival in
EAC.
METHODS
Immunohistochemical analyses and evaluations of HSP27 and HSP70 expression
were performed on all available samples from 93 patients diagnosed with EAC
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between 1990 and 2007 at two university hospitals. Fifteen cases with Barrett’s
metaplasia and 5 control cases from the same patient population were included
in the analysis. HSP expression was quantitatively assessed and classified as high
or low. Kaplan-Meier analyses and Cox regression models adjusting for age and
sex as well as tumor site, stage, and grade were used to evaluate the effect on
survival.
RESULTS
Tumor stage and surgical treatment were the main prognostic factors. High
HSP27 expression in cancer cases was a strong negative predictive factor, with a
mean survival of 23 mo compared to the 49 mo in cases with a low expression (P
= 0.018). The results were similar for HSP70, with a poorer survival of 17 mo in
cases with high HSP70 expression, in contrast to 40 mo (P = 0.006) in cases with a
low expression. A Cox regression survival analysis was performed, adjusting for
possible confounding factors, and higher HSP27 and HSP70 expressions
remained an independent negative prognostic factor. The HSPs’ correlation with
survival was not affected by cancer treatments. When the analysis was adjusted
for all factors, the odds ratios for HSP27 and HSP70 were 3.3 (CI: 1.6–6.6, P =
0.001) and 2.2 (CI: 1.2–3.9, P = 0.02), respectively.
CONCLUSION
HSP27 and HSP70 overexpression is associated with poor survival in EAC, which
is, to the best of our knowledge, reported for the first time.
Key words: Esophageal adenocarcinoma; Heat shock proteins; Heat shock protein 27;
Heat shock protein 70; Overexpression; Survival
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Core tip: Heat shock proteins (HSPs) are classified according to molecular weight into
distinct protein families, and they are present in all human cells. Overexpression of HSPs
is associated with several malignancies and contributes to the development, progression,
and metastasis of cancer, in addition to the inhibition of cellular death. In recent years,
there has been active research into using HSP inhibitors in several malignancies.
Because of the poor prognosis of esophageal adenocarcinoma (EAC), it would be
valuable to find new biomarkers for the development of cancer treatments. We
conducted the present study to analyze the expression of HSP27 and HSP70, and their
association with survival, in patients with EAC.
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INTRODUCTION
Esophageal adenocarcinoma (EAC) is an aggressive disease with a poor prognosis,
and its incidence is increasing in Western countries[1]. At the time of diagnosis, up to
70% of patients present with either local or distant metastasis, reducing the chances of
curative treatment and resulting in a markedly impaired survival[2]. Over the past 10
years, however, we have seen an improvement in survival, especially in local and
locally advanced disease[1], but the overall 5-year survival is nevertheless only 17%[2].
Heat  shock proteins  (HSPs)  are  classified  according to  molecular  weight  (i.e.,
HSP27, HSP60, HSP70, HSP90, and HSP110) into distinct protein families, and they
are  present  in  all  human  cells[3].  They  function  as  molecular  chaperones  in  the
processes of protein folding, cellular signaling, and apoptosis. Overexpression of
HSPs is associated with several malignancies and contributes to the development,
progression, and metastasis of cancer, in addition to the inhibition of cellular death. In
other words, they are essential for cancer growth and tumor survival[3,4]. Conflictingly,
in certain cancers, including esophageal squamous cell carcinoma (SCC)[5], elevated
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HSP27  and  HSP70  expressions  are  associated  with  improved  overall  survival.
Although lower HSP27 and HSP70 expressions have been found among patients with
gastroesophageal reflux disease before and after antireflux surgery when compared to
controls[6],  no previous study exists on the association of HSP27 and HSP70 with
survival among patients with EAC.
Since HSP expression is associated with cancer development and progression, it is
an attractive target for cancer treatment. In recent years, there has been active research
into using HSP inhibitors in several malignancies[4,7]. Because of the poor prognosis of
EAC, it would be valuable to find new biomarkers for the development of cancer
treatments[1].
We conducted the present study to analyze the expression of HSP27 and HSP70,
and their association with survival, in patients with EAC.
MATERIALS AND METHODS
Patients
All patients who were surgically treated for EAC between 1990 and 2007 at Helsinki
University Central Hospital (HUCH) and Tampere University Hospital (TAYS) were
surveyed. In addition, patients who were diagnosed but not treated at TAYS during
the same period were reviewed. All patients who had sufficient tissue material for
analysis were included in the study. Control samples were obtained from the normal
esophageal epithelium adjacent to the tumor. We also included 15 cases with Barrett’s
metaplasia, with or without dysplasia.
Cancer stage and location were assessed in accordance with the American Joint
Committee on Cancer 7th edition staging manual[8]. For statistical reasons, a modified
staging system was implemented where Stage I consisted of stages I–IIA, Stage II of
stages IIB–III, and Stage III of stages IVA and IVB.
Overall survival data was collected from patient records and Statistics Finland in
December 2015.
Samples
All tissue samples, from both endoscopy and surgery, were formalin-preserved and
processed into paraffin blocks. All samples were re-evaluated according to WHO
criteria by two highly experienced pathologists (Paavonen T and Krogerus L). Three
histologically  representative  tumor  sites  (tissue  cores)  were  selected  from  all
surgically obtained samples and placed into tissue micro array (TMA) blocks (Beecher
Instruments, Silver Spring, MD, USA). The diameter of the tissue cores was 1 mm.
Endoscopic samples were processed as routine paraffin blocks.
Immunohistochemistry
The formalin-fixed and paraffin-embedded tissue samples and TMA blocks were cut
into 5 μm sections and placed on Superfrost Plus microscope slides (Menzel-Gläser,
Braunschweig, Germany). Monoclonal antibodies anti-heat shock protein 27 (anti-
HSP27; clone G3.1,  1:400,  Labvision corporation Neomarkers,  FremontCalifornia,
USA) and anti-heat shock protein 70 (anti-HSP70; clone C92F3A-5, 1:50, Stressgen
Bioreagents, Michigan, USA) were used for immunohistochemical staining, which
was done using a Ventana BenchMark LT Automated IHC Stainer (Ventana Medical
System, Arizona, USA) with the Ultraview Universal DAB detection kit (catalogue
No. 760-500, Ventana Medical System, Arizona, USA). The BenchMark LT instrument
and preset was used at each step of the Ventana Ultraview Universal DAB detection
kit to optimize the procedure. The Ventana High Temperature Liquid Coverslip (LCS,
catalogue No: 650-010, Ventana) was applied when appropriate. The Ventana Tris-
based reaction buffer (catalogue No. 950-300, Ventana) was used to rinse the slides
between the steps. Deparaffinization was achieved using Ventana EZ Prep solution
(catalogue No 950-100, Ventana), and epitope retrieval was performed using CC1:
Tris-EDTA buffer pH 8.0 (catalogue No 950-124, Ventana) at 95-100 °C for 30 min with
anti-HSP27, and for 60 min with anti-HSP70. UV-Inhibitor 3% H202 (Ventana) was
used for 4 min at 37 °C to block endogenous peroxidase. The slides were incubated at
37 °C for 32 min with (the) specific antibodies, followed by the application of Ventana
Ultraview HRP Universal Multimer (8 min at 37 °C). Diaminobenzidine was used as a
chromogen  to  detect  antibodies,  and  counterstaining  with  hematoxylin  was
performed before mounting. The above-mentioned process was fully automated for
baking, deparaffinization and antigen retrieval.
Known positive tissue samples were used to confirm staining reliability in all
staining patches[6].
Evaluation of HSP27 and HSP70 expressions
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The expressions of HSP27 and HSP70 were evaluated by two experienced observers
with no knowledge of clinicopathological data. In borderline cases, samples were
reviwed by  a  higly  experienced gastrointestinal  pathologist  and consensus  was
reached. Immunopositivity was measured from one (endoscopic biopsies) or three
(TMA) tumor spots for each patient. The staining intensities were scored based on
sample immunoreactivity as follows: 0 = no stained cells; 1 = faint, 2 = moderate; and
3 = strong positive staining. The percentages of positive epithelial cells (cell positives)
were classified as 0 = no stained cells; 1 = 1%–25% positive cells; 2 = 26%–75% positive
cells;  and  3  ≥  75%  positively  stained  cells.  The  scores  of  staining  intensity  and
positively stained cells were combined and ranged from 0 to 3. HSP expression is
presented as low and high, with a cutoff point of 1.5, the median of the range[6]. In
cases with multiple samples from one patient, the sample with the highest score was
deemed representative.
Statistical methods
The statistical analysis was carried out using SPSS 21.0 (SPSS, Inc., Chicago, Il, USA).
The patients’ age, sex, as well as tumor stage, grade, and site were used as variables.
Kaplan-Meier and Cox regression survival models (adjusting for age and sex; age, sex,
and stage; age, sex, and grade; age, sex, and site; age, sex, stage, grade, and site) were
used for survival analysis. Chi-square test analysis was used on class parameters. The
association between staining intensity and the different variables was analyzed using
multinomial regression models. Correlating expression patterns were analyzed with
Pearson’s  correlation coefficient.  A P  value of  < 0.05 was considered significant.
Survival was calculated from the date of surgery. The survival rates are reported as
means, unless stated otherwise. The statistical methods of this study were reviewed
by Tuomas Selander from Kuopio University Hospital.
Ethics
The study has been approved by the Ethics Committee at HUCH.
RESULTS
In the selected time frame, there were 307 EAC cases. About 96 patients had available
tumor samples, and a total of 151 specimens were located. Sufficient tissue material
for analysis was available in 89 cases for HSP27 (131 specimens) and in 93 cases for
HSP70 (136 specimens). In addition, we analysed 15 Barrett’s esophagus specimens,
with or without dysplasia, from 12 cases. Analysis was also performed on 5 control
samples. HSP27 and HSP70 staining was performed on all available cancer specimens;
patient flow is demonstrated in Figure 1.
About  45.4% of  the  patients  had radical  surgery and 5.4% recieved definitive
oncological treatment with curative intent. 50.8% of the patients were referred to
palliative treatment. The number of surgically treated patients is unusually high,
because  only  operative  cases  were  included  from  HUCH.  Patient  and  tumor
characteristics, surgical procedures, and causes of death are presented in Table 1.
Frequencies of HSP27 and HSP70 immunostaining
HSP27 expression was high in 53 (59.6%) and low in 36 (40.4%) of the cancer cases.
There was no statistical difference in staining frequency in comparison to the Barrett’s
esophagus and control cases. The expression of HSP70 was high in 28 (30.1%) and low
in 65 (69.9%) of the cancer cases. The frequencies were significantly different in the BE
cases, among which the expression was high in 53.3% of the cases (P = 0.025). There
was a strong correlation between HSP27 and HSP70 staining intensities in the cancer
cases (P < 0.001).
The frequencies of  HSP27 and HSP70 immunostaining intensities by stage are
presented in  Table  2  and Table  3.  There  was  no  significant  correlation  between
staining intensity and stage (P = 0.33 and P = 0.45)
Survival
The  mean  and  median  survival  times  for  surgically  treated  patients  were  98.4
(58.5–138.2)  and  58  (17.6–98.4)  mo,  respectively,  while  the  respective  rates  of
inoperable patients were 13.4 (8.6–18.1) and 8 (6.5–9.6) mo (P < 0.001).
Tumor stage was a  strong prognostic  factor  -  a  higher  stage was significantly
associated with poorer survival (P < 0.001) independently of the HSP27 and HSP70
immunostainings (P  < 0.001). Tumor stage did not correlate with HSP expression.
There was a strong correlation between HSP27 and HSP70 immunostainings (P  <
0.001). We also found a correlation between HSP27/70 and tumor grade (P = 0.01 and
P = 0.025, respectively), but the grade was not a prognostic factor. Conservatively
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Figure 1
Figure 1  Patients in selected timeframe (n = 307). Number of tissue samples obtained. “Available for analysis” =
number of samples with sufficient tissue material for heat shock protein analysis. BE: Barrett’s esophagus; HSP: Heat
shock protein.
treated patients  presented significantly more often with high HSP27 and HSP70
expressions, compared to those whom underwent radical surgery. About 67.9% of all
patients with high HSP27, and 75% of those with high HSP70, were inoperable at time
of diagnosis (P < 0.01 and P = 0.01).
High HSP27 expression was  a  strong negative  predictive  factor,  with  a  mean
survival of 23 mo, compared to the survival rate of 49 mo in cases with negative and
low expressions (P = 0.018). The results were similar for HSP70 immunostaining -
cases with a high expression had an inferior survival rate of 17 mo in comparison to
the rate of 40 mo for those with negative or low expression (P = 0.006). Kaplan-Meier
survival functions for HSP27/70 are shown in Figure 2. Patients at risk at 6 mo, 12 mo,
and 36 mo are presented in Table 4.
Subgroup survival analysis was done according to tumor stage. Among HSP27
cancer cases, survival data was available for only six patients with stage I disease.
There  was  no  difference  in  survival  between  high  (4  cases)  and  low  (2  cases)
expressions (P = 0.77). 44 patients with stage II cancer had available survival data, and
survival  among  patients  with  high  HSP27  expression  (27  cases)  was  23.9  mo
compared to 53.2 mo for low expression (17 cases).  This finding was statistically
significant (P  = 0.044).  Among patients with stage III  cancer,  15 had high HSP27
expression and only three had low expression, with survival times of 8.8 mo and 22.3
mo, respectively (P = 0.097).
Similar results were obtained for HSP70. Among the seven stage I cancer patients
with available survival data only one had high HSP70 expression and was still alive at
the  end  of  follow-up.  About  47  patients  had  stage  II  disease  and  there  was  a
statistically significant difference in survival between the 16 cases with high HSP70
expression (17.8 mo) compared to the 31 cases with low expression (43.0 mo) (P =
0.018). About 18 patients had stage III disease with an equal distribution of high and
low expressions, but the difference in survival (14.9 mo and 7.2 mo, respectively) was
not significant (P = 0.137)
Cox regression survival analysis was performed adjusting for age, sex, cancer stage,
tumor grade, and tumor site. Higher HSP27 and HSP70 expressions remained an
independent negative prognostic factor,  and cancer stage was the only analyzed
confounder that was significantly associated with survival. Age, sex, and tumor site
did not affect survival. The HSPs’ effect on survival was not associated with cancer
treatments. When adjusting for all factors, the hazard ratios for HSP27 and HSP70
were 3.3 (95%CI: 1.6–6.6, P = 0.001) and 2.2 (95%CI: 1.2–3.9, P = 0.02), respectively.
DISCUSSION
The main finding in the present study was a significant positive association between
elevated HSP27 and HSP70 expressions and poor survival in EAC. To the best of our
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Table 1  Patient and cancer characteristics
Characteristics n (%)
mean age 64.7 yr (range 38–92 yr)1
Male sex 80%1
Stage
Stage I–IIA 11 (11.8)
Stage IIB–III 56 (60.2)
Stage IVA–IVB 21 (22.6)
Unknown 5 (5.4)
Grade
Grade I 11 (11.8 )
Grade II 32 (34.4 )
Grade III 44 (47.3)
Unknown 6 (6.5 )
Radical surgery 38 (40.9)
Definitive oncological treatment 5 (5.4)
Palliative treatment 50 (53.7)
Cause of death2
Esophageal carcinoma 59 (85.5)
Myocardial infarction 2 (2.9)
Pneumonia 2 (2.9)
Other type of carcinoma 1 (1.4)
Pulmonary embolism 1 (1.4)
Cerebral infarction 1 (1.4)
Unknown 2 (2.9)
180 patients with data available.
269 patients died during follow-up.
knowledge, this is reported herein for the first time. Higher expressions were also
associated with higher tumor grade, but there was no association with pathological
TNM stage or tumor site.
Conservatively treated patients had higher HSP27/70 expressions than those for
whom  radical  surgery  was  an  option.  This  is  consistent  with  the  finding  that
overexpression is associated with higher grade, i.e.,  more aggressive disease, and
therefore more likely to be inoperable at time of diagnosis. We found that patients
with stage II EAC and high HSP27/70 expressions had significantly poorer prognosis,
making them a high risk subgroup.
Previous  studies  have  shown  similar  results  in  connection  with  other
adenocarcinomas,  such  as  colon  and  gastric  carcinoma,  for  both  HSP27[9,10]  and
HSP70[9,11]. Giaginis et al[10] found no effect on survival, but high HSP27 expression was
significantly associated with higher T, N, and M stages, signaling more aggressive
disease. Lee et al[11]  employed study methods similar to those used in the present
study, and while HSP70 was not associated with survival when analyzing the entire
patient population, there was a significant correlation between high expression and
poor survival in adenocarcinomas of the cardia and those of the intestinal type.
There are several studies linking high HSP27 and HSP70 expressions in esophageal
SCC with better overall survival and less aggressive disease[12,13]. It stands to reason
that the expressions in other adenocarcinomas of the gastrointestinal tract would have
similar HSP expressions as in EAC, explaining our opposing findings compared to
SCC. In a meta-analysis conducted in 2015[5], the authors found 5 eligible studies on
HSP27/70 and survival, only one of which was regarding EAC (HSP27)[14]. One study
did not differentiate between EAC/SCC (HSP70)[15] and is therefore not comparable to
the present study. The remaining three were studies on SCC.
Studies regarding HSP27/70 and EAC survival are very scarce. We found only four
studies on the topic, all conducted by the same German research group[14,16-18] and none
of them with the same principal method of analysis as ours, rendering them non-
comparable to present study as such. The main focus in the German group’s studies
has been to identify and verify different protein expression profiles using reverse
phase protein arrays (RPPA), in which HSP27 and HSP70 are a part of a palette of
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Table 2  Frequencies of heat shock protein 27 immunostaining n (%)
HSP27 Stage I - IIA Stage IIB - III Stage IVA - IVB Unknown stage
Low 4 (40) 25 (47.1) 5 (23.8) 2 (40)
High 6 (60) 28 (52.8) 16 (76.2) 3 (60)
No. of cases 10 53 21 5
HSP27 Normal BE BE + LGD BE + HGD
Low 3 (50) 1 (50) 1 (50) 3 (33.3)
High 2 (50) 1 (50) 1 (50) 6 (66.7)
No. of cases 5 2 2 9
BE: Barrett’s esophagus; LGD: Low grade dysplasia HGD: High grade dysplasia.
several proteins. These expression profile analyses did not correlate with the group’s
immunohistochemical (IHC) results[17]. None of the three studies showed a correlation
between IHC HSP27/70 and survival,  nor any prognostic factors including TNM
stage. One of the studies with RPPAs did find that a combination of low HSP27 and
high HER2 correlated with better overall survival in EAC, but no IHC was performed,
therefore  yielding results  that  are  not  comparable  to  ours[14].  Two of  the studies
focused  on  expression  profiles  and  chemotherapy  responses,  and  the  results
contradicted each other[16,17].
A study by Soldes et  al[19]  analyzing 22 EAC patients with or without Barrett’s
metaplasia showed that elevated levels of HSP27 were present in normal esophageal
mucosa, while the expression was significantly lower in Barrett’s esophagus and
carcinoma  samples.  The  authors  speculated  that  one  mechanism  of  carcinoma
development would be the replacement of protective mucosa expressing high levels
of HSP27 with metaplasia expressing low levels of HSP27. In the present study, 54.1%
of  the  cancer  cases  showed  high  HSP27  levels,  with  no  statistical  difference  in
comparison to Barrett’s esophagus or control samples, which differs considerably
from the results of Soldes et al[19]. The study by Soldes et al[19] did not include survival
analysis.
The main limitations of  the present  study are its  retrospective nature and the
relatively  small  sample  size.  The samples  are  from 1990–2007 when oncological
treatment and the surgical approach differed slightly from today’s treatment options,
so the overall survival analysis may not be completely in line with current survival
data. This, however, did not limit the analysis of the HSPs’ prognostic impact, which
was independent of treatments.
In conclusion, we report, for the first time, an association between higher HSP27/70
expressions  and poor  survival  in  EAC.  The  expressions  did  not  differ  from the
Barrett’s esophagus or control samples, rendering them insignificant as diagnostic
markers, but potentially useful as prognostic tools. We found that patients with stage
II EAC and high HSP27/70 expressions had significantly poorer prognosis, making
them  a  possible  target  group  for  HSP  inhibitors.  Further  studies  on  HSP27/70
expressions in EAC are required to evaluate their feasibility and utility as therapeutic
targets.
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Table 3  Frequencies of heat shock protein 70 immunostaining n (%)
HSP70 Stage I - IIA Stage IIB - III Stage IVA - IVB Unknown stage
Low 9 (81.8) 40 (71.4) 12 (57.1) 4 (80)
High 2 (18.2) 16 (28.6) 9 (42.9) 1 (20)
No. of cases 11 56 21 5
HSP70 Normal BE BE + LGD BE + HGD
Low 5 (100) 1 (50) 2 (100) 2 (22.2)
High 0 1 (50) 0 7 (77.8)
No. of cases 5 2 2 9
BE: Barrett’s esophagus; LGD: Low grade dysplasia HGD: High grade dysplasia.
Table 4  Overall survival and (number of patients at risk) at 6, 12 and 36 mo
mean survival OS 6 mo OS 1 yr OS 3 yr
HSP27 (72)
Low (23) 49 91.3% (21) 60.9% (14) 39.1% (9)
High (49) 23 69.4% (34) 44.9% (22) 16.3% (8)
HSP70 (76)
Low (49) 40 87.8% (43) 61.2% (30) 30.6% (15)
High (27) 17 59.3% (16) 33.3% (9) 11.1% (3)
OS: Overall survival.
Figure 2
Figure 2  Survival (mo) associated with heat shock protein 27 (A) and heat shock protein 70 (B) expression.
ARTICLE HIGHLIGHTS
Research background
Overexpression  of  heat  shock  proteins  (HSPs)  is  associated  with  several  malignancies.  It
contributes to the development, progression, and metastasis of cancer, and to the inhibition of
cellular death. There has been active research into using HSP inhibitors in several malignancies
in recent years.
Research motivation
Because of the poor prognosis of esophageal adenocarcinoma (EAC), it would be valuable to find
new biomarkers for the development of cancer treatments.
WJCC https://www.wjgnet.com February 6, 2019 Volume 7 Issue 3
Söderström HK et al. Overexpression of HSP27 and HSP70 in esophageal adenocarcinoma
267
Research objectives
In the present study, the authors intend to analyze the expression of HSP27 and HSP70, and their
association with survival, in patients with EAC.
Research methods
Immunohistochemical  analyses  and  evaluations  of  HSP27  and  HSP70  expression  were
performed on all available samples from 93 patients diagnosed with EAC. From the same patient
population, 15 cases with Barrett’s metaplasia and 5 control cases were included in the analysis.
HSP expression was quantitatively assessed and classified as high or low. Kaplan-Meier analyses
and Cox regression models were used to evaluate the effect on survival.
Research results
Tumor stage and surgical treatment were the main prognostic factors. High HSP27 expression in
cancer cases was a strong negative predictive factor, with a mean survival of 23 mo vs the 49 mo
in cases with a low expression. The results were similar for HSP70, with a poorer survival of 17
mo in cases with high HSP70 expression, in contrast to 40 mo in cases with a low expression.
Higher HSP27 and HSP70 expressions remained an independent negative prognostic factor. The
HSPs’ correlation with survival was not affected by cancer treatments.
Research conclusions
To the best of our knowledge, reported for the first time, HSP27 and HSP70 overexpression is
associated with poor survival in EAC.
Research perspectives
To evaluate their feasibility and utility as therapeutic targets,  further studies on HSP27/70
expressions in EAC are required.
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